US Patent Number
The present invention relates, in general, to attenuated equine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated equine influenza viruses having modifications to an equine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations.
Mount Sinai School of Medicine, New York, NY (US), University of Kentucky, Lexington, KY (US)
Palese, Peter; Garcia-Sastre, Adolfo; and Chambers, Thomas, "Genetically Engineered Equine Influenza Virus and Uses Thereof" (2012). Veterinary Science Faculty Patents. 2.